The first International Conference on Vaccines Research & Development (Vaccines R&D-2015) concluded successfully on November 04, 2015. The three-day conference organized by United Scientific Group (USG) during November 02-04, 2015 at DoubleTree by Hilton, Baltimore BWI airport hotel with the theme “A New Era in Vaccine Discovery”.
Vaccines R&D-2015 featured many highly informative and interactive sessions to encourage the exchange of ideas across a broad range of disciplines in vaccine industry. The conference has gathered researchers, scientists, academicians, experts from industries and other professionals in vaccine community to exchange and discuss their original research results, practical development experiences, technological achievements and new ideas for developing future vaccines.
Vaccines R&D-2015 Conference report
The milestone day of the conference in the beautiful Baltimore city has been started with the keynote speeches from Dr. Jay A. Berzofsky, on “Cancer Vaccines: Translation from Mice to Human Clinical Trials” followed by Dr. Robert W. Malone, on “Ebola Vaccine in 12 months, Global Village, and the Need for Speed” and by Dr. Samir N. Khleif on “Vaccines in Combination Immune Therapy for Cancer”.
On behalf of Dr. Norman W. Baylor his colleague Dr. Paul Price from Biologics Consulting Group, Inc. USA delivered the keynote talk on “Regulatory Perspective on the Evaluation of New Vaccine Technologies”. The keynote on “Vaccines Against Invasive Salmonella Infections” was presented by Dr. Myron M. Levine and the session concluded with a presentation on “Immune Protection Inducing Synthetic Protein Structures (IMPIPS): The New Vaccines” by Dr. Manuel Elkin Patarroyo.
The post lunch session continued with symposium on “PfSPZ-Based Malaria Vaccines from Concept to Licensure” by Sanaria Inc followed by featured presentations and poster presentations.
The unrivalled event on the day 1 is the CEO-CSO conclave witnessed by an elite group of CEOs and CSOs attended the conference with an agenda on how a global fund for vaccine development be structured, and how would they be able to use an enhanced global infectious disease surveillance, detection, diagnosis and modeling capability to enable them to more efficiently develop vaccines for infectious disease epidemics.
The penultimate day of the conference continued with presentations by the pioneers in the field covering the topics from novel vaccines discovery, development & formulation; to cancer vaccines & clinical trials.
Vaccines R&D 2015 conference has been concluded with eloquent presentations from world-class experts on different areas including basic vaccinology, passive vaccines, HIV/AIDS vaccines, influenza vaccines, HPV vaccines and the Ebola outbreak.
USG is obliged to the committee members of Vaccines R&D-2015, sponsors and exhibitors (Sanofi Pasteur, InDevR, LumaCyte, AERAS and Cellular Technology Limited) and the delegates around the world for their outstanding support and participation.